BNP Paribas Financial Markets Takes Position in Aerovate Therapeutics, Inc. (NASDAQ:AVTE)

BNP Paribas Financial Markets purchased a new stake in Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 54,688 shares of the company's stock, valued at approximately $145,000. BNP Paribas Financial Markets owned 0.19% of Aerovate Therapeutics as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Allostery Investments LP bought a new stake in Aerovate Therapeutics during the fourth quarter valued at about $2,254,000. ADAR1 Capital Management LLC lifted its position in shares of Aerovate Therapeutics by 720.7% during the 4th quarter. ADAR1 Capital Management LLC now owns 928,016 shares of the company's stock worth $2,459,000 after purchasing an additional 814,941 shares during the last quarter. Nantahala Capital Management LLC bought a new stake in Aerovate Therapeutics during the 4th quarter valued at approximately $1,280,000. Affinity Asset Advisors LLC grew its holdings in Aerovate Therapeutics by 33.3% in the 4th quarter. Affinity Asset Advisors LLC now owns 800,000 shares of the company's stock valued at $2,120,000 after buying an additional 200,000 shares during the last quarter. Finally, Deltec Asset Management LLC bought a new position in Aerovate Therapeutics in the 4th quarter worth approximately $514,000.

Aerovate Therapeutics Trading Up 0.7%

NASDAQ:AVTE traded up $0.05 during trading hours on Wednesday, hitting $7.25. 390,996 shares of the company traded hands, compared to its average volume of 18,966. Aerovate Therapeutics, Inc. has a twelve month low of $43.75 and a twelve month high of $884.98. The firm has a 50-day moving average of $46.56 and a 200 day moving average of $74.45. The stock has a market capitalization of $210.14 million, a price-to-earnings ratio of -2.42 and a beta of 0.95.

Aerovate Therapeutics (NASDAQ:AVTE - Get Free Report) last issued its earnings results on Friday, April 25th. The company reported ($3.15) EPS for the quarter, beating analysts' consensus estimates of ($10.50) by $7.35. Equities research analysts predict that Aerovate Therapeutics, Inc. will post -2.64 earnings per share for the current fiscal year.

Aerovate Therapeutics Announces Dividend

The company also recently announced a dividend, which was paid on Monday, April 28th. Stockholders of record on Friday, April 25th were issued a $84.00 dividend. The ex-dividend date of this dividend was Tuesday, April 29th.

About Aerovate Therapeutics

Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.